Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?

Conclusion.Women with metastatic melanoma and NSCLC are more likely to experience irAEs compared with men. We also observed differences between sexes in the frequency of certain irAEs. Larger studies are needed to investigate the mechanisms underlying these associations.Implications for Practice.The results of this study suggest that women may be at a higher risk for immune‐related adverse events (irAEs) compared with men when treated with anti‐programmed cell death protein 1 therapy. In addition, women were more likely to develop certain irAEs, including endocrinopathies and pneumonitis. Close follow‐up of women undergoing treatment with immune checkpoint inhibitors will allow clinicians to diagnose these treatment‐related complications early, potentially reducing their associated morbidity and mortality. In addition, a possible association between irAEs and response to therapy was observed.

Source: The Oncologist - November 12, 2019 Category: Cancer & Oncology Authors: Narȷust Duma, Azzouqa Abdel-Ghani, Siddhartha Yadav, Katherine P. Hoversten, Clay T. Reed, Andrea N. Sitek, Elizabeth Ann L. Enninga, Jonas Paludo, Jesus Vera Aguilera, Konstantinos Leventakos, Yanyan Lou, Lisa A. Kottschade, Haidong Dong, Aaron S. Tags: Melanoma and Cutaneous Malignancies, Symptom Management and Supportive Care, Geriatric Oncology Immuno ‐ Source Type: research